Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and ...

Amgen has climbed to a recent close of US$407.44 after a strong multi year run, which puts fresh focus on whether that price ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Cantor Fitzgerald set a USD 440 target from USD 400 on October 8, 2026. Amgen stock was EUR 376.93 on October 13, 2026.

Sept 22 () - Amgen said on Tuesday its experimental drug to treat an ‌autoimmune disease that attacks the body's ‌moisture-producing glands met the main goal of reducing disease ​activity in a ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Amgen stock was quoted at EUR 368.63 by Lang & Schwarz at 8:21 a.m. CEST on October 14, 2026. The bid was EUR 367.75 and the ...

Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (AMGN +2.11%) started the year strong, ...

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

14 January 2025, Bavaria, Munich: The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025.

Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. | Amgen has shed light on its ...